
    
      This is a prospective, non-interventional and pharmaco-epidemiological study of participants
      with IBD. The study will provide the real-life data of treatment effectiveness and safety of
      vedolizumab in adult participants with UC or CD.

      The study will enroll approximately 300 participants. All participants will be enrolled in
      one observational group:

      Vedolizumab

      Data will be collected and observed for 24 months in the participants who will be freely
      chosen by physicians to prescribe vedolizumab at the end of consultation in the recruitment
      period.

      This multi-center trial will be conducted in France. The overall time to participate in this
      study is 36 months, including participant's recruitment period of 12 months and treatment
      period of 24 months. Participants will make a minimum of 4 follow-up visits to the clinic in
      treatment period at Month 6, 12, 18, and 24.
    
  